Home > Insider Trading > Filing (0001602264-14-000003)

Filing Details

Accession Number:: 0001602264-14-000003
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2014-08-07 15:18:19
Reporting Period:: 2014-08-05

Filing Date:: 2014-08-07
Accepted Time:: 2014-08-07 15:18:19
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1501756	Avalanche Biotechnologies Inc.	AAVL	Biological Products, (No Disgnostic Substances) (2836)	205258327

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1602263	Vhcp Management Ii, Llc	C/O Venrock 3340 Hillview Ave. Palo Alto CA 94304	No	No	Yes	No
1602264	Venrock Healthcare Capital Partners Ii, L.p.	C/O Venrock 3340 Hillview Ave. Palo Alto CA 94304	No	No	Yes	No
1615983	Vhcp Co-Investment Holdings Ii, Llc	C/O Venrock 3340 Hillview Ave. Palo Alto CA 94304	No	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2014-08-05	1,965,471	$0.00	1,965,471	No	4	C	Indirect	By Funds
Common Stock	Acquisiton	2014-08-05	400,000	$17.00	2,365,471	No	4	P	Indirect	By Funds

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	C	Indirect	By Funds
No	4	P	Indirect	By Funds

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series B Preferred Stock	Disposition	2014-08-05	1,965,471	$0.00	1,965,471	$0.00

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0			No	4	C	Indirect

Footnotes

Each share of Series B Preferred Stock automatically converted into one share of Issuer's Common Stock upon the consummation of the Issuer's initial public offering (the "IPO").
Venrock Associates VI, L.P. ("VA6") holds an aggregate of 911,193 shares, Venrock Partners VI, L.P. ("VP6") holds an aggregate of 71,543 shares, Venrock Healthcare Capital Partners, L.P. ("VHCP") holds an aggregate of 830,805 shares and VHCP Co-Investment Holdings, LLC ("Co-Invest") holds an aggregate of 151,930 shares.
Venrock Management VI, LLC, Venrock Partners Management VI, LLC and VHCP Management, LLC (collectively, the "Venrock GP Entities") are the sole general partners or manager, as applicable, of VA6, VP6, VHCP and Co-Invest (collectively, the "Funds"), respectively, and have voting and investment power over the shares held by the Funds. Anders Hove and Bong Koh are the managing members of VHCP Management, LLC and may be deemed to beneficially own the shares held by VHCP and Co-Invest. Each of the Venrock GP Entities and Drs. Hove and Koh disclaims beneficial ownership of the shares held by the Funds, except to the extent of their respective indirect pecuniary interests therein.
In the IPO, VHCP purchased an aggregate of 101,443 shares, Co-Invest purchased an aggregate of 18,557 shares, Venrock Healthcare Capital Partners II, L.P. ("VHCP2") purchased an aggregate of 235,455 shares and VHCP Co-Investment Holdings II, LLC ("Co-Invest 2") purchased an aggregate of 44,545 shares.
VA6 holds an aggregate of 911,193 shares, VP6 holds an aggregate of 71,543 shares, VHCP holds an aggregate of 932,248 shares, Co-Invest holds an aggregate of 170,487 shares, VHCP2 holds an aggregate of 235,455 shares and Co-Invest 2 holds an aggregate of 44,545 shares.
Venrock Management VI, LLC, Venrock Partners Management VI, LLC, VHCP Management, LLC and VHCP Management II, LLC (collectively, the "Venrock GP I & II Entities") are the sole general partners or managers, as applicable, of VA6, VP6, VHCP, VHCP2, Co-Invest and Co-Invest 2 (collectively, the "Venrock Funds"), respectively, and have voting and investment power over the shares held by the Venrock Funds. Anders Hove and Bong Koh are the managing members of VHCP Management, LLC and VHCP Management II, LLC and may be deemed to beneficially own the shares held by VHCP, VHCP2, Co-Invest and Co-Invest 2. Each of the Venrock GP I & II Entities and Drs. Hove and Koh disclaims beneficial ownership of the shares held by the Venrock Funds, except to the extent of their respective indirect pecuniary interests therein.
The Series B Preferred Stock automatically converted into shares of Issuer's Common Stock on a 1:1 basis upon the completion of Issuer's IPO.
The expiration date is not relevant to the conversion of these securities.